Novavax Aktie
WKN DE: A2PKMZ / ISIN: US6700024010
24.07.2025 15:06:01
|
Novavax Says H5N1 Vaccine Candidate Showed Immunogenicity In Preclinical Study
(RTTNews) - Novavax, Inc. (NVAX) Thursday said that its H5N1 avian pandemic influenza vaccine candidate induced robust immune responses in nonhuman primates.
Results from the study suggest that a single dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza. Additionally, data showed that the vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration.
These results were published in Nature Communications.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novavax Inc.mehr Nachrichten
05.08.25 |
Ausblick: Novavax zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Novavax Inc.mehr Analysen
Aktien in diesem Artikel
Novavax Inc. | 7,35 | 3,78% |
|